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DEVELOPMENT AND VALIDATION OF THE 
NEW HEALTH-RELATED QUALITY OF LIFE
INSTRUMENT SPECIFIC TO PATIENTS WITH
CORONARY ARTERY DISEASE (CAD) IN
POLAND: POL-CAD
Jaworski R1, Muszynska A2, Halik J3, Harmata W4, Czech M1,
Pachocki R1
1Servier Poland Research Institute, Warsaw, Poland; 2Medical
University, Warsaw, Poland; 3Centre for the Informative
Systems in Health Care, Warsaw, Poland; 4Military Institute of
Chemistry and Radiometry, Warsaw, Poland
OBJECTIVES: To develop a new instrument applicable
to quality of life (QoL) assessment in patients suffering
from coronary artery disease and to evaluate reliability of
the results obtained with the use of this instrument in 
the Polish setting. METHODS: Construction of the 
POL-CAD questionnaire is based on a literature review
concerning different quality of life measures, experts’
opinions in cardiology ﬁeld, and interviews with patients.
POL-CAD includes 17 items clustered into 5 domains:
coronary pains, physical functioning, emotional status,
social activity and satisfaction with treatment. The score
for each domain is the sum of the items with the 0–20
range. The summary measure consists of the total score
for all domains. The validation study in Poland involved
57 patients with different Canadian Cardiovascular
Society (CCS) classiﬁcation and consisted of pre-testing
and two repeated QoL measures at a 4-week interval.
Visual analogue scale was also included, to measure indi-
viduals’ preferences and evaluate utility values for differ-
ent CAD states. RESULTS: Most of the patients (84.2%)
reported complete understanding of the questions and
73.7% were able to complete POL-CAD unaided. The
mean values of the total QoL score achieved were: 70.6
± 12.7 in CCS I, 57.7 ± 9.5 in CCS II and 50.1 ± 12.2 in
CCS III. Observed differences were statistically signiﬁcant
(p < 0.05). Results obtained for the stable patients were
fully repeatable at four weeks intervals. The differences
for the patients who changed the CCS over time were also
statistically signiﬁcant (p < 0.05). A very high correlation
0.9 > r > 0.7 of the coronary pain score with the total
score and also the high correlation 0.7 > r > 0.5 with the
scores for the remaining domains were observed. CON-
CLUSIONS: Quality of life assessment made with the use
of the POL-CAD correlates strongly with the states of
CAD according to CCS classiﬁcation. POL-CAD allows
provision of reliable assessment of the health related
quality of life in CAD patients.
PCV80
EARLY EVOLUTION, DETERMINANTS AND
PREDICTIVE POWER OF HEALTH RELATED
QUALITY OF LIFE IN A MULTICENTRIC
POPULATION OF PATIENTS WITH HEART
FAILURE
Permanyer-Miralda G, Soriano N
University Hospital Vall d’Hebron, Barcelona, Spain
OBJECTIVE: The early results of a prospective one year
follow up study of HRQL of patients (pts) admitted to
32 general hospitals during a 10-month period for CHF
are reported. METHODS: Diagnosis was established
based on the European Society of Cardiology criteria 
and HRQL was measured with the SF-36 health proﬁle.
RESULTS: Of the 849 already recruited pts, information
of HRQL is available for 605pts at baseline and for 506
at one month. Forty-two percent were women, mean age
was 70 (from 17 to 96), 62% had previous diagnosis of
heart failure, 42% had diabetes mellitus, 40% had at least
one important comorbid condition, 49% had biventricu-
lar heart failure at admission and 37% had functional
class IV (New York Heart Association classiﬁcation).
Heart failure pts had low scores in all dimensions of the
SF-36 and improvement after admission was only modest.
At one month evaluation the Physical Component
Summary (PCS) score of the SF-36 increased from 33 to
35, and its determinants were PCS at baseline (beta coef-
ﬁcient of 5 for an increase of 10 units) and biventricular
heart failure (beta coefﬁcient of -3.37). The Mental Com-
ponent Summary (MCS) increased from 41 to 44 and its
determinants were PCS (beta coef. of 1.7 for a 10 units
increase) and MCS (beta coef. 4.2 for a 10 units increase)
at baseline, gender (beta coef. of -3.4 for women) and
comorbidity (beta coef. of -2.47). Eight percent of
patients died during the ﬁrst month, being PCS at base-
line (odds ratio of 0.96 for one unit increase) and age
(odds ratio of 1.09 for each year) independent predictors
of this short-term mortality. CONCLUSION: Compared
with pts with coronary syndromes these patients had
worse scores of general health perceptions and mental
health and also less improvement.
DIABETES
DIABETES—Clinical Outcomes Studies
PDB1
IMPROVED GLYCAEMIC CONTROL AND LESS
HYPOGLYCAEMIA WITH INSULIN GLARGINE
COMPARED WITH NPH INSULIN IN PATIENTS
WITH TYPE 2 DIABETES LEADS TO FEWER
LONG-TERM COMPLICATIONS—RESULTS OF
THE DIABETES MELLITUS SIMULATION MODEL
Maxion-Bergemann S1, Müller E1, Bergemann R1,Walleser S1,
Huppertz E2
1Institute for Medical Outcome Research (IMOR) GmbH,
Lörrach, Germany; 2Aventis Pharma Deutschland GmbH, Bad
Soden/Taunus, Germany
OBJECTIVES: To investigate the effect of insulin glargine
(glargine) versus NPH insulin (NPH) on long-term out-
comes in Type 2 diabetes using the Diabetes Mellitus
Model (DMM). METHODS: The DMM predicts numer-
ous short- and long-term complications over 10 years,
based on published studies. The main inﬂuence on out-
comes is HbA1c, which is simulated over time. The version
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of the DMM used in this analysis takes into account
results of a regression analysis (pooled glargine versus
NPH clinical trials), which demonstrates a more favour-
able relationship between HbA1c decrease and hypogly-
caemia incidence for glargine versus NPH. Different
cohorts of 10,000 patients with Type 2 diabetes taking
glargine or NPH were assumed. The 3 scenarios tested
differed in target HbA1c attainable by glargine versus
NPH (scenario 1: D = 0.13%; scenario 2: D = 0.44%; sce-
nario 3: D = 0.85%), corresponding to realistic possible
improvements with comparable hypoglycaemia. Assump-
tions were based on clinical trials for scenarios 1 and 2,
and on the regression analysis for scenario 3. RESULTS:
The following relative risks (RR; glargine/NPH) were
obtained for scenarios 1, 2, and 3 respectively: 0.97, 0.89
and 0.81 for long-term microvascular complications
(need for renal dialysis: 0.97, 0.88, and 0.79); 0.99, 0.95,
and 0.91 for long-term macrovascular complications
(non-fatal myocardial infarction: 0.98, 0.95, and 0.88);
0.96, 0.88, and 0.79 for diabetic foot syndrome; and
0.99, 0.94, and 0.90 for mortality. The RR for a noctur-
nal hypoglycaemic event (0.81, 0.92 and 1.01) was con-
sistent with the regression analysis. The RR reductions
ranged from 1% in the less optimistic scenario to >20%
in the “best case” scenario. Varying mean baseline HbA1c
and duration of diabetes in sensitivity analyses did not
alter these outcomes. CONCLUSIONS: Assuming com-
parable hypoglycaemia, the better glycaemic control
(HbA1c reduction) achieved with glargine than with NPH
would lead to reduced long-term complications and mor-
tality rate, based on this model.
PDB2
IS THERE A GAIN WITH THE PAIN?
ASSESSMENT OF THE RELATIONSHIP
BETWEEN SELF-REPORTED ADHERENCE TO
SELF-MONITORING OF BLOOD GLUCOSE
(SMBG) AND HBA1C LEVELS AMONG TYPE 2
DIABETICS
Vincze G, Barner JC, Lopez DA
University of Texas at Austin, Austin,TX, USA
Conﬂicting information exists in the literature regarding
the merit of frequent SMBG to control blood glucose
levels among type 2 diabetics. The American Diabetes
Association (ADA) recommends SMBG to reach and
maintain normal or near-normal glucose levels among
both type 1 and type 2 diabetics. OBJECTIVE: The objec-
tive of this study was to assess whether self-reported
adherence to SMBG was related to HbA1C among type
2 diabetics. METHODS: Type 2 diabetics from a county
family clinic served as the study population. Participants
completed a self-administered survey during seminars
held at the clinic. Chart reviews were conducted to
retrieve baseline (at the time of the seminar) and follow-
up (within one year after the seminar) HbA1C levels, as
well as indication for change in pharmacotherapy. Mul-
tiple regression was used to assess the relationships
between SMBG adherence and HbA1C, while controlling
for demographic (i.e., age, race, and income) and biolog-
ical (i.e., duration of diabetes, comorbidities, change 
in pharmacotherapy, and baseline HbA1C) variables. A
priori signiﬁcance level of .05 was chosen. RESULTS:
Participants (n = 158) were 56.9 (SD: 12.3) years old,
non-white (70.1%), with annual family income between
$20,000 and $30,000, on average. Their adherence to
SMBG was 49.2% (SD: 40.3), which was not associated
with follow-up HbA1C level. Duration of diabetes,
change in pharmacotherapy, and the number of compli-
cations were signiﬁcantly and positively associated with
follow-up HbA1C. CONCLUSIONS: SMBG adherence
was not signiﬁcantly related to follow-up HbA1C among
type 2 diabetics. Maintaining normal or near-normal
blood glucose levels may be more likely associated with
adherence to diet, exercise, and medication. Health prac-
titioners should view SMBG as a tool, rather than a
therapy by itself, and recommend its use to those patients
who can and are willing to act based upon the results.
PDB3
CLAIMS DATA MEASUREMENTS OF
MEDICATION ADHERENCE AND METABOLIC
OUTCOMES IN PATIENTS WITH TYPE 2
DIABETES (DM2)
Pladevall M, Loomis LA,Williams K, Xi H,Akkerman N,
Elston-Lafata J
Henry Ford Health System, Detroit, MI, USA
OBJECTIVES: To use claims data to estimate the associ-
ation between adherence to medications and clinical out-
comes in DM2 patients. METHODS: Using automated
data from a large health maintenance organization, 
we identiﬁed a sample of 644 patients, age 18 years 
diagnosed with DM2, hypertension, and hyper-
cholesterolemia who receive treatment with either 
cardiovascular or antidiabetic medications between
1999–2001. Patients taking insulin were excluded. We
measured adherence to three classes of drugs, biguanides,
HMG-CoA reductase inhibitors (CoA-I), and ACE-
inhibitors (ACE). Within each drug class, adherence was
measured for those patients who ﬁlled at least one pre-
scription per year. Body mass index and blood pressure
measurements were obtained by medical record ion. Non-
adherence was calculated as a continuous measure of
medication gaps (CMG), which is the proportion of days
without medication during the period of observation. T-
tests or non-parametric tests were used, where appropri-
ate, to compare baseline characteristics and differences in
clinical outcomes. Associations between clinical outcomes
and CMG were estimated using correlation coefﬁcients.
Linear regression models were used to adjust for socio-
demographic and clinical characteristics. RESULTS:
Correlation coefﬁcients were 0.25 for non-adherence 
to biguanides and HbA1c (p < 0.01), 0.32 for non-
adherence to CoA-I and LDL (p < 0.01), and 0.16 for
non-adherence to ACE and SBP (p < 0.01). When com-
